PharmaEngine in Taiwan
E-mail: info@pharmaengine.com
Web: https://www.pharmaengine.com/
Address:
-
Office PharmaEngine in Taiwan
11F, 10 Minsheng East Road, Sec. 3 Taipei 104
Phone: +886 2 2515–8228
Fax: +886 2 2515–7558
Clinical Trials sponsored by PharmaEngine
-
PharmaEngineFullførtMetastatisk tykktarmskreftTaiwan
-
PharmaEngineFullført
-
PharmaEngineRekrutteringAkutt myeloid leukemi | Lymfom, mantelcelleAustralia
-
PharmaEngineHar ikke rekruttert ennåAvansert solid svulst | Metastatisk solid svulst
-
PharmaEngineFullførtIldfaste solide svulsterTaiwan
-
PharmaEngineAvsluttet
-
PharmaEngineAvsluttetPlateepitelkarsinom i hode og nakkeTaiwan
-
PharmaEngineFullførtNeoplasmer i bukspyttkjertelenTaiwan, Forente stater
-
PharmaEngineFullførtNeoplasmer i magen | Neoplasmer i spiserøretKorea, Republikken, Spania, Taiwan, Bosnia og Herzegovina, Storbritannia, Kroatia
About PharmaEngine
PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 2 projects in the pipeline. ONIVYDE® (PEP02, MM-398, nal-IRI), a new formulation of an anti-cancer drug (irinotecan) for the patients with gemcitabine-treated metastatic pancreatic cancer, so far, ONIVYDE® has received marketing approval in more than 40 countries, including Taiwan, US, EU, Australia, Canada, South Korea, and Japan. PEP07, a checkpoint kinase 1 (Chk1) inhibitor, which targets the DNA Damage Response (DDR) network, is currently in the pre-clinical stage.